In this case report, Gad and colleagues performed corneal confocal microscopy to assess for evidence of nerve regeneration ...

Novo Nordisk has nominated semaglutide for inclusion in the FDA’s Demonstrable Difficulties for Compounding list, which ...

Semaglutide, the glucagon-like peptide 1 receptor agonist from Novo Nordisk A/S, which has seemingly improved every disease it’s been tested on, was a focus at Kidney Week 2024, where researchers ...

It's no secret that doctors are helping many people lose weight by prescribing GLP-1 medications like Ozempic, Wegovy, ...

The brain has GLP -1 receptors in abundance and, though very little drug seems to be able to cross the blood-brain barrier ...

Topline results were announced from a cardiovascular outcomes study evaluating oral semaglutide in patients with type 2 diabetes.

In a 24-week trial, semaglutide led to a 52% reduction in albuminuria and improved kidney health in individuals with chronic ...

An oral formulation of semaglutide, taken daily, is more effective at reducing the risk of major adverse cardiovascular ...

This analysis from the FLOW trial showed that once-weekly subcutaneous semaglutide 1.0 mg significantly lowered the risk of ...

However, tirzepatide, a long-acting glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and glucagon-like ...

Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for ...

People with Type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer's compared ...